Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 10/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RPA1 | P27694 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6444454 | 0.98 | ALPL (0.49) | ALPLCA9TP53HCAR3CA12 | |
| SCHEMBL6109157 | 0.85 | ALPL (0.44) | ALPLCA9TP53HCAR3CA12 | |
| SCHEMBL6211786 | 0.84 | HPGD (0.40) | ALPLCA9TP53HCAR3HPGD | |
| SCHEMBL2658376 | 0.82 | PLA2G10 (0.44) | ALPLCA9HPGDTSHRKDM4E | |
| SCHEMBL1498674 | 0.80 | ALPL (0.46) | ALPLCA9TP53HCAR3CA12 | |
| SCHEMBL1455921 | 0.79 | MAPK1 (0.61) | ALPL | |
| Hydrochloric Acid SCHEMBL31067451 | 0.78 | ALPL (0.45) | ALPLCA9TP53HCAR3CA12 | |
| SCHEMBL1815054 | 0.78 | ALPL (0.49) | ALPLTP53HPGDTSHRKDM4E | |
| SCHEMBL352985 | 0.78 | HPGD (0.39) | ALPLHCAR3HPGDTSHRKDM4E | |
| SCHEMBL6111053 | 0.76 | ALPL (0.42) | ALPLCA9TP53HCAR3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2112150-B1 | Improved raf inhibitors | FORMA THERAPEUTICS INC (US) | 2013-10-16 | — | — | EP | claimed |
| US-8232283-B2 | Raf inhibitors | FORMA THERAPEUTICS, INC. (US) | 2012-07-31 | — | — | US | claimed |
| WO-2009130015-A1 | IMPROVED RAF INHIBITORS | GPC BIOTECH AG (DE) | 2009-10-29 | — | — | WO | claimed |
| EP-2112150-A1 | Improved raf inhibitors | GPC Biotech AG (DE) | 2009-10-28 | — | — | EP | claimed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| CN-118307564-A | Nitrogen-containing heterocyclic compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-116621846-B | Bicyclic heterocycle and tricyclic heterocycle compounds, and preparation method and medical application thereof | 华润医药研究院（深圳）有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116621846-A | Bicyclic heterocycle and tricyclic heterocycle compounds, and preparation method and medical application thereof | 华润医药研究院（深圳）有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-3999183-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Ono Pharmaceutical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
| EP-2229391-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| WO-2009130015-A1 | IMPROVED RAF INHIBITORS | GPC BIOTECH AG (DE) | 2009-10-29 | — | — | WO | disclosed |
| EP-2112150-A1 | Improved raf inhibitors | GPC Biotech AG (DE) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009077766-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| CN-1878769-A | Cytokine inhibitors | KEMIA INC (US) | 2006-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ALPL 747/4885CA9 605/4885TP53 784/4885 |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM1B, KDM5D | ALPL 3465/4885CA9 2732/4885TP53 281/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | ALPL 4093/4885CA9 4073/4885TP53 3172/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | ALPL 3230/4885CA9 2297/4885TP53 1529/4885 |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | ALPL 747/4885CA9 605/4885TP53 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.